9VC Fundamental Analysis - ATAI BECKLEY NV

Fundamental Rating

Overall 9VC gets a fundamental rating of 3 out of 10. We evaluated 9VC against 54 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for 9VC as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, 9VC is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 9VC has reported negative net income.

In the past year 9VC has reported a negative cash flow from operations.

9VC had negative earnings in each of the past 5 years.

9VC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

9VC's Return On Assets of -62.24% is on the low side compared to the rest of the industry. 9VC is outperformed by 83.64% of its industry peers.

Looking at the Return On Equity, with a value of -93.44%, 9VC is doing worse than 80.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-62.24%
ROE	-93.44%
ROIC	N/A

ROA(3y)-52.42%

ROA(5y)-70.02%

ROE(3y)-67.79%

ROE(5y)-86.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for 9VC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

9VC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, 9VC has more shares outstanding

9VC has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, 9VC has a worse debt to assets ratio.

2.2 Solvency

9VC has an Altman-Z score of 6.45. This indicates that 9VC is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 6.45, 9VC belongs to the best of the industry, outperforming 89.09% of the companies in the same industry.

There is no outstanding debt for 9VC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.45

ROIC/WACCN/A

WACC7.43%

2.3 Liquidity

A Current Ratio of 7.90 indicates that 9VC has no problem at all paying its short term obligations.

The Current ratio of 9VC (7.90) is better than 98.18% of its industry peers.

A Quick Ratio of 7.90 indicates that 9VC has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 7.90, 9VC belongs to the best of the industry, outperforming 98.18% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.9
Quick Ratio	7.9

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

9VC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.

The Revenue has decreased by -1.91% in the past year.

Measured over the past years, 9VC shows a very negative growth in Revenue. The Revenue has been decreasing by -75.28% on average per year.

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-75%

Revenue 1Y (TTM)-1.91%

Revenue growth 3Y-75.28%

Revenue growth 5YN/A

Sales Q2Q%1772.5%

3.2 Future

9VC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.71% yearly.

9VC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 226.91% yearly.

EPS Next Y30.67%

EPS Next 2Y22.22%

EPS Next 3Y14.8%

EPS Next 5Y12.71%

Revenue Next Year468.61%

Revenue Next 2Y-38.09%

Revenue Next 3Y24.11%

Revenue Next 5Y226.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

9VC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year 9VC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as 9VC's earnings are expected to grow with 14.80% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.22%

EPS Next 3Y14.8%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

9VC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ATAI BECKLEY NV

FRA:9VC (12/5/2025, 7:00:00 PM)

3.789

-0.01 (-0.24%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-12 2025-11-12/bmo

Earnings (Next)03-16 2026-03-16/amc

Inst Owners12.05%

Inst Owner ChangeN/A

Ins Owners3.7%

Ins Owner ChangeN/A

Market Cap1.38B

Revenue(TTM)308.00K

Net Income(TTM)-149.27M

Analysts83.53

Price Target10.57 (178.97%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-74.59%

Min EPS beat(2)-131.54%

Max EPS beat(2)-17.64%

EPS beat(4)1

Avg EPS beat(4)-48.58%

Min EPS beat(4)-131.54%

Max EPS beat(4)17.15%

EPS beat(8)3

Avg EPS beat(8)-34.15%

EPS beat(12)6

Avg EPS beat(12)-5.69%

EPS beat(16)8

Avg EPS beat(16)-13.8%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.83%

PT rev (3m)7.96%

EPS NQ rev (1m)-1.99%

EPS NQ rev (3m)-0.52%

EPS NY rev (1m)-26.55%

EPS NY rev (3m)-34.65%

Revenue NQ rev (1m)12.5%

Revenue NQ rev (3m)33.33%

Revenue NY rev (1m)24.85%

Revenue NY rev (3m)37.1%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5202.92
P/FCF	N/A
P/OCF	N/A
P/B	10.03
P/tB	10.25
EV/EBITDA	N/A

EPS(TTM)-0.7

EYN/A

EPS(NY)-0.4

Fwd EYN/A

FCF(TTM)-0.21

FCFYN/A

OCF(TTM)-0.19

OCFYN/A

SpS0

BVpS0.38

TBVpS0.37

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-62.24%
ROE	-93.44%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-52.42%

ROA(5y)-70.02%

ROE(3y)-67.79%

ROE(5y)-86.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1203.88%
Cap/Sales	3521.75%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.9
Quick Ratio	7.9
Altman-Z	6.45

F-Score4

WACC7.43%

ROIC/WACCN/A

Cap/Depr(3y)268.35%

Cap/Depr(5y)673.01%

Cap/Sales(3y)220.74%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-75%

EPS Next Y30.67%

EPS Next 2Y22.22%

EPS Next 3Y14.8%

EPS Next 5Y12.71%

Revenue 1Y (TTM)-1.91%

Revenue growth 3Y-75.28%

Revenue growth 5YN/A

Sales Q2Q%1772.5%

Revenue Next Year468.61%

Revenue Next 2Y-38.09%

Revenue Next 3Y24.11%

Revenue Next 5Y226.91%

EBIT growth 1Y18.39%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.8%

EBIT Next 3Y-18.5%

EBIT Next 5Y-6.5%

FCF growth 1Y3.34%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y14.22%

OCF growth 3YN/A

OCF growth 5YN/A

ATAI BECKLEY NV / 9VC.DE FAQ

What is the ChartMill fundamental rating of ATAI BECKLEY NV (9VC.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE.

What is the valuation status of ATAI BECKLEY NV (9VC.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ATAI BECKLEY NV (9VC.DE). This can be considered as Overvalued.

What is the profitability of 9VC stock?

ATAI BECKLEY NV (9VC.DE) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for 9VC stock?

The Earnings per Share (EPS) of ATAI BECKLEY NV (9VC.DE) is expected to grow by 30.67% in the next year.

ATAI BECKLEY NV (9VC.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ATAI BECKLEY NV / 9VC.DE FAQ

What is the ChartMill fundamental rating of ATAI BECKLEY NV (9VC.DE) stock?

What is the valuation status of ATAI BECKLEY NV (9VC.DE) stock?

What is the profitability of 9VC stock?

Can you provide the expected EPS growth for 9VC stock?